PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 1982 February; 69(2): 315–326.
PMCID: PMC370981

Role of Epinephrine-mediated β-Adrenergic Mechanisms in Hypoglycemic Glucose Counterregulation and Posthypoglycemic Hyperglycemia in Insulin-dependent Diabetes Mellitus

Abstract

Initially euglycemic (overnight insulin-infused) patients with insulin-dependent diabetes mellitus (IDDM), compared with nondiabetic controls, exhibit similar, but somewhat delayed plasma glucose nadirs, delayed glucose recovery from hypoglycemia, and posthypoglycemic hyperglycemia after the rapid intravenous injection of 0.075 U/kg of regular insulin. These abnormalities are associated with and potentially attributable to markedly diminished glucagon secretory responses, partially reduced epinephrine secretory responses and delayed clearance of injected insulin in the diabetic patients. Because glucagon normally plays a primary role in hypoglycemic glucose counterregulation and enhanced epinephrine secretion largely compensates for glucagon deficiency, we hypothesized that patients with IDDM, who exhibit diminished glucagon secretory responses to hypoglycemia, would be more dependent upon epinephrine to promote glucose recovery from hypoglycemia than are nondiabetic persons. To test this hypothesis, glucose counterregulation during β-adrenergic blockade with propranolol was compared with that during saline infusion in both nondiabetic controls and in patients with IDDM. Glucose counterregulation was unaffected by β-adrenergic blockade in controls. In contrast, glucose recovery from hypoglycemia was significantly impaired during β-adrenergic blockade in diabetic patients. This finding confirms the hypothesis that such patients are more dependent upon epinephrine-mediated β-adrenergic mechanisms to promote glucose recovery from hypoglycemia and indicates that the measured deficiency of glucagon secretion is functionally important in patients with IDDM. Further, in the time frame of these studies, posthypoglycemic hyperglycemia was prevented by β-adrenergic blockade in these patients. There was considerable heterogeneity among the diabetic patients with respect to the degree to which β-adrenergic blockade limited the posthypoglycemic rise in plasma glucose. This rise was directly related to the degree of residual glucagon secretion and inversely related to plasma-free insulin concentrations.

Thus, we conclude: (a) that patients with IDDM are, to varying degrees, dependent upon epinephrine-mediated β-adrenergic mechanisms to promote glucose recovery from hypoglycemia and that the degree of this dependence upon epinephrine is an inverse function of the residual capacity to secrete glucagon in response to hypoglycemia in individual patients; (b) that sympathoadrenal activation, coupled with the inability to secrete insulin, plays an important role in the pathogenesis of posthypoglycemic hyperglycemia in patients with IDDM.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Clarke WL, Santiago JV, Thomas L, Ben-Galim E, Haymond MW, Cryer PE. Adrenergic mechanisms in recovery from hypoglycemia in man: adrenergic blockade. Am J Physiol. 1979 Feb;236(2):E147–E152. [PubMed]
  • Gerich J, Davis J, Lorenzi M, Rizza R, Bohannon N, Karam J, Lewis S, Kaplan R, Schultz T, Cryer P. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol. 1979 Apr;236(4):E380–E385. [PubMed]
  • Rizza RA, Cryer PE, Gerich JE. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. 1979 Jul;64(1):62–71. [PMC free article] [PubMed]
  • Cryer PE. Glucose counterregulation in man. Diabetes. 1981 Mar;30(3):261–264. [PubMed]
  • Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science. 1973 Oct 12;182(4108):171–173. [PubMed]
  • Benson JW, Jr, Johnson DG, Palmer JP, Werner PL, Ensinck JW. Glucagon and catecholamine secretion during hypoglycemia in normal and diabetic man. J Clin Endocrinol Metab. 1977 Mar;44(3):459–464. [PubMed]
  • Maher TD, Tanenberg RJ, Greenberg BZ, Hoffman JE, Doe RP, Goetz FC. Lack of glucagon response to hypoglycemia in diabetic autonomic neuropathy. Diabetes. 1977 Mar;26(3):196–200. [PubMed]
  • Santiago JV, Clarke WL, Shah SD, Cryer PE. Epinephrine, norepinephrine, glucagon, and growth hormone release in association with physiological decrements in the plasma glucose concentration in normal and diabetic man. J Clin Endocrinol Metab. 1980 Oct;51(4):877–883. [PubMed]
  • Rizza RA, Cryer PE, Haymond MW, Gerich JE. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest. 1980 Mar;65(3):682–689. [PMC free article] [PubMed]
  • Viberti GC, Keen H, Bloom SR. Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects. Metabolism. 1980 Sep;29(9):866–872. [PubMed]
  • Viberti GC, Keen H, Bloom SR. Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics. Metabolism. 1980 Sep;29(9):873–879. [PubMed]
  • Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet. 1979 Mar 3;1(8114):458–462. [PubMed]
  • Leichter SB, Pagliara AS, Grieder MH, Pohl S, Rosai J, Kipnis DM. Uncontrolled diabetes mellitus and hyperglucagonemia associated with an islet cell carcinoma. Am J Med. 1975 Feb;58(2):285–293. [PubMed]
  • HALES CN, RANDLE PJ. Immunoassay of insulin with insulin-antibody precipitate. Biochem J. 1963 Jul;88:137–146. [PubMed]
  • SCHALCH DS, PARKER ML. A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA. Nature. 1964 Sep 12;203:1141–1142. [PubMed]
  • Farmer RW, Pierce CE. Plasma cortisol determination: radioimmunoassay and competitive protein binding compared. Clin Chem. 1974 Apr;20(4):411–414. [PubMed]
  • Kuzuya H, Blix PM, Horwitz DL, Steiner DF, Rubenstein AH. Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes. 1977 Jan;26(1):22–29. [PubMed]
  • Cryer PE, Santiago JV, Shah S. Measurement of norepinephrine and epinephrine in small volumes of human plasma by a single isotope derivative method: response to the upright posture. J Clin Endocrinol Metab. 1974 Dec;39(6):1025–1029. [PubMed]
  • Cahill GF, Jr, Herrera MG, Morgan AP, Soeldner JS, Steinke J, Levy PL, Reichard GA, Jr, Kipnis DM. Hormone-fuel interrelationships during fasting. J Clin Invest. 1966 Nov;45(11):1751–1769. [PMC free article] [PubMed]
  • LOWRY OH, PASSONNEAU JV, HASSELBERGER FX, SCHULZ DW. EFFECT OF ISCHEMIA ON KNOWN SUBSTRATES AND COFACTORS OF THE GLYCOLYTIC PATHWAY IN BRAIN. J Biol Chem. 1964 Jan;239:18–30. [PubMed]
  • Hilsted J, Madsbad S, Krarup T, Sestoft L, Christensen NJ, Tronier B, Galbo H. Hormonal, metabolic, and cardiovascular responses to hypoglycemia in diabetic autonomic neuropathy. Diabetes. 1981 Aug;30(8):626–633. [PubMed]
  • Leveston SA, Shah SD, Cryer PE. Cholinergic stimulation of norepinephrine release in man. Evidence of a sympathetic postganglionic axonal lesion in diabetic adrenergic neuropathy. J Clin Invest. 1979 Aug;64(2):374–380. [PMC free article] [PubMed]
  • Cryer PE, Silverberg AB, Santiago JV, Shah SD. Plasma catecholamines in diabetes. The syndromes of hypoadrenergic and hyperadrenergic postural hypotension. Am J Med. 1978 Mar;64(3):407–416. [PubMed]
  • Cryer PE, Rizza RA, Haymond MW, Gerich JE. Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man. Metabolism. 1980 Nov;29(11 Suppl 1):1114–1118. [PubMed]
  • Blackard WG, Heidingsfelder SA. Adrenergic receptor control mechanism for growth hormone secretion. J Clin Invest. 1968 Jun;47(6):1407–1414. [PMC free article] [PubMed]
  • Campbell LV, Kraegen EW, Lazarus L. Defective blood glucose counter-regulation in diabetics is a selective form of autonomic neuropathy. Br Med J. 1977 Dec 10;2(6101):1527–1529. [PMC free article] [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation